Table 4.
Predictive performance of CSF biomarkers for clinical progression among 139 samples
| Clinical variables | Biomarkers | |||||
|---|---|---|---|---|---|---|
| Aβ42 | T-tau | P-tau | Aβ42/Aβ40 | t-tau/Aβ42 | p-tau/Aβ42 | |
| F, P value | ||||||
| CDR | 4.139, 0.008 | 1.512, 0.215 | 1.127, 0.341 | 3.627, 0.015 | 2.831, 0.041 | 3.639, 0.015 |
| CDR-SB | 8.308, 0.0001 | 1.584, 0.197 | 1.011, 0.390 | 5.982, 0.001 | 4.472, 0.005 | 6.416, 0.0001 |
| BDS-ADL | 3.471, 0.018 | 1.634, 0.185 | 0.749, 0.525 | 2.975, 0.034 | 2.199, 0.092 | 3.095, 0.030 |
| SBT | 1.566, 0.201 | 1.500, 0.218 | 0.661, 0.578 | 2.002, 0.117 | 2.365, 0.074 | 1.720, 0.167 |
| MMSE | 3.434, 0.020 | 2.362, 0.076 | 1.358, 0.260 | 4.227, 0.007 | 4.277, 0.007 | 5.030, 0.003 |
| Constructional praxis | 2.921, 0.038 | 1.596, 0.195 | 0.335, 0.800 | 2.071, 0.109 | 2.244, 0.088 | 2.088, 0.107 |
| Clock drawing | 3.295, 0.024 | 3.482, 0.019 | 1.356, 0.261 | 4.751, 0.004 | 5.091, 0.003 | 5.034, 0.003 |
Ten subjects with AD-like CSF signature (2, 1, and 7 at first, second, and third follow-ups, respectively) and 9 subjects with normal CSF signature (1, 4, and 4 at third, second, and first follow-ups, respectively) were lost to follow-up. Numbers in bold indicate the variables with significance under ANCOVA analysis
CDR Clinical Dementia Rating scale, CDR-SB CDR-Sum of Boxes, BDS-ADL Blessed Dementia Scale-Activities of Daily Living, SBT Short Blessed Test, MMSE Mini-Mental State Examination